

## Addendum

**Addendum: Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation****Karam Khaddour<sup>1</sup>, Joshua Dowling<sup>2</sup>, Jiayi Huang<sup>3</sup>, Martha Council<sup>4</sup>, David Chen<sup>4</sup>, Lynn Cornelius<sup>4</sup>, Tanner Johanns<sup>1</sup>, Sonika Dahiya<sup>5</sup> and George Ansstas<sup>1</sup>**<sup>1</sup>Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA<sup>2</sup>Department of Neurological Surgery, Washington University School of Medicine, St. Louis, Missouri, USA<sup>3</sup>Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA<sup>4</sup>Division of Dermatology, Washington University School of Medicine, St. Louis, Missouri, USA<sup>5</sup>Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA**Published:** February 11, 2023**Copyright:** © 2023 Khaddour et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.**This article has an addendum:** Informed patient consent was obtained.Original article: Oncotarget. 2020; 11:4836–4844. <https://doi.org/10.18632/oncotarget.27848>